IMMUNIC, INC. — Director's Dealing 2019

Apr 22, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: IMMUNIC, INC. (IMUX)
CIK: 0001280776
Period of Report: 2019-04-12

Reporting Person: Ossipow Vincent (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1371494	Indirect

Footnotes

F1: On April 12, 2019, pursuant to an Exchange Agreement, dated as of January 6, 2019, between the Issuer (then known as Vital Therapies, Inc.), Immunic AG ("Immunic"), and the shareholders of Immunic party thereto (the "Exchange Agreement"), the holders of Immunic ordinary shares exchanged all of their outstanding shares for shares of Issuer common stock, resulting in Immunic becoming a wholly-owned subsidiary of the Issuer (the "Transaction"). Immediately following the Transaction, the Issuer changed its name to "Immunic, Inc." In connection with the Transaction, the Reporting Person was appointed Director of the Issuer.

F2: The Reporting Person is a Partner of Global Life Bioventure V S.a r.l., which is the record holder of 1,371,494 shares of common stock of the Issuer, and exercises voting power over such shares. The Reporting Person hereby disclaims beneficial ownership of any such shares beneficially owned by such entity except to the extent of any pecuniary interest therein and this Form shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purposes.